Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus Lenalidomide Maintenance in High-Risk Multiple Myeloma Post-ASCT
NCT05776979Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2023; status: recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05776979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776979.